HSBC in Hong Kong has rehired Emily Kwong as a managing director and head of healthcare for Asia Pacific.
Kwong has joined from CLSA, where she’d been an MD in the coverage and corporate finance group, focused on healthcare and TMT, since June 2017. She worked on a number of landmark biotech deals, including the 2018 dual listing of drug maker BeiGene. Kwong was an MD in Evercore in Hong Kong from 2012 to 2017, responsible for its Asean cross-border M&A business.
This is Kwong’s second stint at HSBC. She was there between 2009 and 2012 as a director in the consumer and retail group within investment banking, according to her LinkedIn profile. In her new role, Kwong will be tasked with growing market share for HSBC in the booming mainland healthcare sector. China is the world’s second-largest biopharmaceutical market.
HSBC chairman Mark Tucker said earlier this week that the bank will speed up its Asian expansion, which was first announced 11 months ago. HSBC will be “bringing forward investment and building more capabilities” in 2021 and will tap “substantial opportunities” in China’s Greater Bay Area, which includes Hong Kong, he added.
Kwong worked in director-level healthcare roles at UBS (2005 to 2008) and Merrill Lynch (2008 to 2009).
Have a confidential story, tip, or comment you’d like to share? Email: email@example.com or Telegram: @simonmortlock. You can also follow me on LinkedIn.